ArticleFrontiers in immunology2026
Comprehensive analysis of fatty acid desaturase 3 in clear cell renal cell carcinoma: insights into tumor progression, immune microenvironment, and clinical outcomes.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clear cell renal cell carcinoma (ccRCC or KIRC) is a malignant neoplasm characterized by reprogrammed lipid metabolism. Fatty acid desaturase 3 (FADS3), a sphingoid Δ14Z desaturase, is required for the synthesis of unsaturated fatty acids in tumor biology. However, the role of FADS3 in ccRCC progression and prognosis and in modulating the tumor immune microenvironment (TIME) remains to be elucidated. Methods: The ccRCC transcriptomic datasets were obtained from the TCGA, GEO, and GTEx databases. Mendelian randomization (MR) and single-cell RNA sequencing analyses were used to investigate the associations of FADS3 with lipid metabolism, and differential expression genes in ccRCC. Bioinformatics analysis was also used to investigate the association of FADS3 expression with tumor progression, prognosis, TIME, and potential pathogenic mechanism in ccRCC. FADS3 expression in ccRCC cell lines was confirmed by qRT-PCR, western blotting, RNA-Seq. FADS3 roles in ccRCC were assessed by functional assays including cell proliferation, migration, invasion, and colony formation using wild-type and FADS3-knockdown cell lines. Results: Lipid metabolism was found to be upregulated in ccRCC tumor tissues based on comprehensive bioinformatic analysis. FADS3 was among the upregulated genes associated with lipid metabolism, which was expressed not only in ccRCC tumor cells but also in cells of the TIME, such as tumor-associated macrophages (TAMs). High FADS3 expression remodeled the TIME and predicted poor prognosis in ccRCC. Functional assays demonstrated that FADS3 knockdown markedly suppressed ccRCC cell proliferation, migration and invasion. Transcriptomic analyses further suggested that FADS3 may promote ccRCC progression through activation of oncogenic and metabolic signaling pathways, such as the PI3K/Akt pathway. Conclusion: FADS3 is a lipid metabolism-associated oncogenic driver in ccRCC, and its upregulation remodels the TIME and predicts poor prognosis. FADS3 may represent a potential therapeutic target for ccRCC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.